NR4A1 and breast cancer: Some BC subtypes, such as HER2 and triple negative (HER2 negative and hormonal receptors negative), are at high risk of brain recurrence even after initial treatment [51,52], with the former more likely to have controlled extra-cranial disease, making brain control a major issue.